Cargando…

Analysis of risk factors for determining the need for prostate biopsy in patients with negative MRI

To analyze the clinical characteristics of patients with negative biparametric magnetic resonance imaging (bpMRI) who didn’t need prostate biopsies (PBs). A total of 1,012 male patients who underwent PBs in the First Affiliated Hospital of Nanjing Medical University from March 2018 to November 2019,...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Linghui, Qi, Feng, Cheng, Yifei, Zhang, Lei, Cao, Dongliang, Cheng, Gong, Hua, Lixin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7960992/
https://www.ncbi.nlm.nih.gov/pubmed/33723287
http://dx.doi.org/10.1038/s41598-021-83802-z
_version_ 1783665160197505024
author Liang, Linghui
Qi, Feng
Cheng, Yifei
Zhang, Lei
Cao, Dongliang
Cheng, Gong
Hua, Lixin
author_facet Liang, Linghui
Qi, Feng
Cheng, Yifei
Zhang, Lei
Cao, Dongliang
Cheng, Gong
Hua, Lixin
author_sort Liang, Linghui
collection PubMed
description To analyze the clinical characteristics of patients with negative biparametric magnetic resonance imaging (bpMRI) who didn’t need prostate biopsies (PBs). A total of 1,012 male patients who underwent PBs in the First Affiliated Hospital of Nanjing Medical University from March 2018 to November 2019, of 225 had prebiopsy negative bpMRI (defined as Prostate Imaging Reporting and Data System (PI-RADS 2.1) score less than 3). The detection efficiency of clinically significant prostate cancer (CSPCa) was assessed according to age, digital rectal examination (DRE), prostate volume (PV) on bpMRI, prostate-specific antigen (PSA) and PSA density (PSAD). The definition of CSPCa for Gleason score > 6. Univariate and multivariable logistic regression analysis were used to identify predictive factors of absent CSPCa on PBs. Moreover, absent CSPCa contained clinically insignificant prostate cancer (CIPCa) and benign result. The detection rates of present prostate cancer (PCa) and CSPCa were 27.11% and 16.44%, respectively. Patients who were diagnosed as CSPCa had an older age (P < 0.001), suspicious DRE (P < 0.001), a smaller PV (P < 0.001), higher PSA value (P = 0.008) and higher PSAD (P < 0.001) compared to the CIPCa group and benign result group. PSAD < 0.15 ng/ml/cm(3) (P = 0.004) and suspicious DRE (P < 0.001) were independent predictors of absent CSPCa on BPs. The negative forecast value of bpMRI for BP detection of CSPCa increased with decreasing PSAD, mainly in patients with naive PB (P < 0.001) but not in prior negative PB patients. 25.33% of the men had the combination of negative bpMRI, PSAD < 0.15 ng/ml/cm(3) and PB naive, and none had CSPCa on repeat PBs. The incidence of PB was determined, CSPCa was 1.59%, 0% and 16.67% in patients with negative bpMRI and PSAD < 0.15 ng/ml/cm(3), patients with negative bpMRI, PSAD < 0.15 ng/ml/cm(3) and biopsy naive and patients with negative bpMRI, PSAD < 0.15 ng/ml/cm(3) and prior negative PB, separately. We found that a part of patients with negative bpMRI, a younger age, no suspicious DRE and PSAD < 0.15 ng/ml/cm(3) may securely avoid PBs. Conversely PB should be considered in patients regardless of negative bpMRI, especially who with a greater age, obviously suspicious DRE, significantly increased PSA value, a significantly small PV on MRI and PSAD > 0.15 ng/ml/cm(3).
format Online
Article
Text
id pubmed-7960992
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-79609922021-03-19 Analysis of risk factors for determining the need for prostate biopsy in patients with negative MRI Liang, Linghui Qi, Feng Cheng, Yifei Zhang, Lei Cao, Dongliang Cheng, Gong Hua, Lixin Sci Rep Article To analyze the clinical characteristics of patients with negative biparametric magnetic resonance imaging (bpMRI) who didn’t need prostate biopsies (PBs). A total of 1,012 male patients who underwent PBs in the First Affiliated Hospital of Nanjing Medical University from March 2018 to November 2019, of 225 had prebiopsy negative bpMRI (defined as Prostate Imaging Reporting and Data System (PI-RADS 2.1) score less than 3). The detection efficiency of clinically significant prostate cancer (CSPCa) was assessed according to age, digital rectal examination (DRE), prostate volume (PV) on bpMRI, prostate-specific antigen (PSA) and PSA density (PSAD). The definition of CSPCa for Gleason score > 6. Univariate and multivariable logistic regression analysis were used to identify predictive factors of absent CSPCa on PBs. Moreover, absent CSPCa contained clinically insignificant prostate cancer (CIPCa) and benign result. The detection rates of present prostate cancer (PCa) and CSPCa were 27.11% and 16.44%, respectively. Patients who were diagnosed as CSPCa had an older age (P < 0.001), suspicious DRE (P < 0.001), a smaller PV (P < 0.001), higher PSA value (P = 0.008) and higher PSAD (P < 0.001) compared to the CIPCa group and benign result group. PSAD < 0.15 ng/ml/cm(3) (P = 0.004) and suspicious DRE (P < 0.001) were independent predictors of absent CSPCa on BPs. The negative forecast value of bpMRI for BP detection of CSPCa increased with decreasing PSAD, mainly in patients with naive PB (P < 0.001) but not in prior negative PB patients. 25.33% of the men had the combination of negative bpMRI, PSAD < 0.15 ng/ml/cm(3) and PB naive, and none had CSPCa on repeat PBs. The incidence of PB was determined, CSPCa was 1.59%, 0% and 16.67% in patients with negative bpMRI and PSAD < 0.15 ng/ml/cm(3), patients with negative bpMRI, PSAD < 0.15 ng/ml/cm(3) and biopsy naive and patients with negative bpMRI, PSAD < 0.15 ng/ml/cm(3) and prior negative PB, separately. We found that a part of patients with negative bpMRI, a younger age, no suspicious DRE and PSAD < 0.15 ng/ml/cm(3) may securely avoid PBs. Conversely PB should be considered in patients regardless of negative bpMRI, especially who with a greater age, obviously suspicious DRE, significantly increased PSA value, a significantly small PV on MRI and PSAD > 0.15 ng/ml/cm(3). Nature Publishing Group UK 2021-03-15 /pmc/articles/PMC7960992/ /pubmed/33723287 http://dx.doi.org/10.1038/s41598-021-83802-z Text en © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Liang, Linghui
Qi, Feng
Cheng, Yifei
Zhang, Lei
Cao, Dongliang
Cheng, Gong
Hua, Lixin
Analysis of risk factors for determining the need for prostate biopsy in patients with negative MRI
title Analysis of risk factors for determining the need for prostate biopsy in patients with negative MRI
title_full Analysis of risk factors for determining the need for prostate biopsy in patients with negative MRI
title_fullStr Analysis of risk factors for determining the need for prostate biopsy in patients with negative MRI
title_full_unstemmed Analysis of risk factors for determining the need for prostate biopsy in patients with negative MRI
title_short Analysis of risk factors for determining the need for prostate biopsy in patients with negative MRI
title_sort analysis of risk factors for determining the need for prostate biopsy in patients with negative mri
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7960992/
https://www.ncbi.nlm.nih.gov/pubmed/33723287
http://dx.doi.org/10.1038/s41598-021-83802-z
work_keys_str_mv AT lianglinghui analysisofriskfactorsfordeterminingtheneedforprostatebiopsyinpatientswithnegativemri
AT qifeng analysisofriskfactorsfordeterminingtheneedforprostatebiopsyinpatientswithnegativemri
AT chengyifei analysisofriskfactorsfordeterminingtheneedforprostatebiopsyinpatientswithnegativemri
AT zhanglei analysisofriskfactorsfordeterminingtheneedforprostatebiopsyinpatientswithnegativemri
AT caodongliang analysisofriskfactorsfordeterminingtheneedforprostatebiopsyinpatientswithnegativemri
AT chenggong analysisofriskfactorsfordeterminingtheneedforprostatebiopsyinpatientswithnegativemri
AT hualixin analysisofriskfactorsfordeterminingtheneedforprostatebiopsyinpatientswithnegativemri